Sorafenib blocks tumor angiogenesis by targeting vascular endothelial growth factor receptor-2/-3 (VEGFR-2/-3) and platelet-derived growth factor receptor-beta (PDGFR-beta) tyrosine kinases (67) (Figure 1). This evidence concerns the gene KDR and neoplasm.